Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance
An in vitro study was designed to evaluate the uptake of sestamibi (MIBI) in P-glycoprotein (Pgp) and glutathione-associated (GSH) multidrug-resistant (MDR) cell lines. MIBI uptake was studied in various human breast carcinoma cell lines, i.e. in wild-type (MCF7/wt) cells, in adriamycin-resistant (M...
Gespeichert in:
| Veröffentlicht in: | European Journal of Nuclear Medicine 1996-05, Vol.23 (5), p.568-570 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 570 |
|---|---|
| container_issue | 5 |
| container_start_page | 568 |
| container_title | European Journal of Nuclear Medicine |
| container_volume | 23 |
| creator | KABASAKAL, L ÖZKER, K HAYWARD, M AKANSEL, G GRIFFITH, O ISITMAN, A. T HELLMAN, R COLLIER, D |
| description | An in vitro study was designed to evaluate the uptake of sestamibi (MIBI) in P-glycoprotein (Pgp) and glutathione-associated (GSH) multidrug-resistant (MDR) cell lines. MIBI uptake was studied in various human breast carcinoma cell lines, i.e. in wild-type (MCF7/wt) cells, in adriamycin-resistant (MCF7/adr) cells which express Pgp and in melphalan-resistant (MCF7/mph) cells with increased levels of GSH. The effects of buthiomine sulphoximine (BSO) and verapamil on MIBI uptake were also studied in the MCF7/mph and MCF7/adr cells respectively. The cells were incubated for 1 h with a dose of 0.1 MBq thallium-201 and technetium-99m MIBI. Both MIBI and 201Tl uptakes were higher for MCF7/mph cells than for the other cells studied. The mean MIBI uptake in MCF7/adr cells was significantly lower than that in MCF7/wt cells (1.9%+/-0.5% vs 3. 1%.0.6%; P |
| doi_str_mv | 10.1007/BF00833393 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00833393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78029933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-18a46e74336312d218297967af4824cd0bcbf026b577fa052ff7e11ab2d1fa783</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhq0KVJalF-5IPqAekALjOOuPI1T9QKrEpZyjiTPeNSTO4kmQ-u9J1VU5zeF99GjeV4j3Cj4rAPvl2w2A01p7fSY2yihfWXD-ldiAbqAy3ts34i3zLwBoGr07F-fOeAdGb8TfBwqHTHNaxsr7UTLxjGPqklyOM_4mmbI8LCNm2RVCnmXAElKeRpSBhkEOKRPLPvFxwMeU93I_LDPOhzRlqpB5Cgln6mVfln1ViNOqz4HeidcRB6aL092KnzfXD1d31f2P2-9XX--roJWaK-WwMWQbrY1WdV8rV3vrjcXYuLoJPXShi1CbbmdtRNjVMVpSCru6VxGt01tx-ew9lunPsnZrx8RPj2OmaeHWOqi9X6fbik_PYCgTc6HYHksasTy2Ctqnkdv_I6_wh5N16UbqX9DTqmv-8ZQjBxxiWSsnfsE0GKdX1z8PW4Ub</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78029933</pqid></control><display><type>article</type><title>Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>KABASAKAL, L ; ÖZKER, K ; HAYWARD, M ; AKANSEL, G ; GRIFFITH, O ; ISITMAN, A. T ; HELLMAN, R ; COLLIER, D</creator><creatorcontrib>KABASAKAL, L ; ÖZKER, K ; HAYWARD, M ; AKANSEL, G ; GRIFFITH, O ; ISITMAN, A. T ; HELLMAN, R ; COLLIER, D</creatorcontrib><description>An in vitro study was designed to evaluate the uptake of sestamibi (MIBI) in P-glycoprotein (Pgp) and glutathione-associated (GSH) multidrug-resistant (MDR) cell lines. MIBI uptake was studied in various human breast carcinoma cell lines, i.e. in wild-type (MCF7/wt) cells, in adriamycin-resistant (MCF7/adr) cells which express Pgp and in melphalan-resistant (MCF7/mph) cells with increased levels of GSH. The effects of buthiomine sulphoximine (BSO) and verapamil on MIBI uptake were also studied in the MCF7/mph and MCF7/adr cells respectively. The cells were incubated for 1 h with a dose of 0.1 MBq thallium-201 and technetium-99m MIBI. Both MIBI and 201Tl uptakes were higher for MCF7/mph cells than for the other cells studied. The mean MIBI uptake in MCF7/adr cells was significantly lower than that in MCF7/wt cells (1.9%+/-0.5% vs 3. 1%.0.6%; P <0.01). Verapamil treatment increased the MIBI uptake in MCF7/adr cells (to 2.6%.0.3%; P <0.05). Treatment of MCF7/mph cells with BSO resulted in a significant reduction in GSH content (from 243.2+/-81.1 nmol/mg protein to 17.6+/-4.4 nmol/mg protein; P <0. 001). However, MIBI uptake in BSO-treated and untreated MCF7/mph cells was similar (4.43%+/-0.5% and 5.93%+/-1.7%, respectively; P >0. 1). This study suggests that the uptake of MIBI is not diminished by glutathione-associated drug resistance and that MIBI uptake in a tumour sample does not necessarily indicate that a cancer is sensitive to drugs.</description><identifier>ISSN: 0340-6997</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/BF00833393</identifier><identifier>PMID: 8698063</identifier><identifier>CODEN: EJNMD9</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ; Biological and medical sciences ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Drug Resistance, Neoplasm ; Female ; Glutathione - metabolism ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Radionuclide Imaging ; Technetium Tc 99m Sestamibi - pharmacokinetics ; Thallium Radioisotopes - pharmacokinetics ; Tumor Cells, Cultured ; Tumors</subject><ispartof>European Journal of Nuclear Medicine, 1996-05, Vol.23 (5), p.568-570</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-18a46e74336312d218297967af4824cd0bcbf026b577fa052ff7e11ab2d1fa783</citedby><cites>FETCH-LOGICAL-c311t-18a46e74336312d218297967af4824cd0bcbf026b577fa052ff7e11ab2d1fa783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3068308$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8698063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KABASAKAL, L</creatorcontrib><creatorcontrib>ÖZKER, K</creatorcontrib><creatorcontrib>HAYWARD, M</creatorcontrib><creatorcontrib>AKANSEL, G</creatorcontrib><creatorcontrib>GRIFFITH, O</creatorcontrib><creatorcontrib>ISITMAN, A. T</creatorcontrib><creatorcontrib>HELLMAN, R</creatorcontrib><creatorcontrib>COLLIER, D</creatorcontrib><title>Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance</title><title>European Journal of Nuclear Medicine</title><addtitle>Eur J Nucl Med</addtitle><description>An in vitro study was designed to evaluate the uptake of sestamibi (MIBI) in P-glycoprotein (Pgp) and glutathione-associated (GSH) multidrug-resistant (MDR) cell lines. MIBI uptake was studied in various human breast carcinoma cell lines, i.e. in wild-type (MCF7/wt) cells, in adriamycin-resistant (MCF7/adr) cells which express Pgp and in melphalan-resistant (MCF7/mph) cells with increased levels of GSH. The effects of buthiomine sulphoximine (BSO) and verapamil on MIBI uptake were also studied in the MCF7/mph and MCF7/adr cells respectively. The cells were incubated for 1 h with a dose of 0.1 MBq thallium-201 and technetium-99m MIBI. Both MIBI and 201Tl uptakes were higher for MCF7/mph cells than for the other cells studied. The mean MIBI uptake in MCF7/adr cells was significantly lower than that in MCF7/wt cells (1.9%+/-0.5% vs 3. 1%.0.6%; P <0.01). Verapamil treatment increased the MIBI uptake in MCF7/adr cells (to 2.6%.0.3%; P <0.05). Treatment of MCF7/mph cells with BSO resulted in a significant reduction in GSH content (from 243.2+/-81.1 nmol/mg protein to 17.6+/-4.4 nmol/mg protein; P <0. 001). However, MIBI uptake in BSO-treated and untreated MCF7/mph cells was similar (4.43%+/-0.5% and 5.93%+/-1.7%, respectively; P >0. 1). This study suggests that the uptake of MIBI is not diminished by glutathione-associated drug resistance and that MIBI uptake in a tumour sample does not necessarily indicate that a cancer is sensitive to drugs.</description><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Glutathione - metabolism</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Radionuclide Imaging</subject><subject>Technetium Tc 99m Sestamibi - pharmacokinetics</subject><subject>Thallium Radioisotopes - pharmacokinetics</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0340-6997</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1v1DAQhq0KVJalF-5IPqAekALjOOuPI1T9QKrEpZyjiTPeNSTO4kmQ-u9J1VU5zeF99GjeV4j3Cj4rAPvl2w2A01p7fSY2yihfWXD-ldiAbqAy3ts34i3zLwBoGr07F-fOeAdGb8TfBwqHTHNaxsr7UTLxjGPqklyOM_4mmbI8LCNm2RVCnmXAElKeRpSBhkEOKRPLPvFxwMeU93I_LDPOhzRlqpB5Cgln6mVfln1ViNOqz4HeidcRB6aL092KnzfXD1d31f2P2-9XX--roJWaK-WwMWQbrY1WdV8rV3vrjcXYuLoJPXShi1CbbmdtRNjVMVpSCru6VxGt01tx-ew9lunPsnZrx8RPj2OmaeHWOqi9X6fbik_PYCgTc6HYHksasTy2Ctqnkdv_I6_wh5N16UbqX9DTqmv-8ZQjBxxiWSsnfsE0GKdX1z8PW4Ub</recordid><startdate>19960501</startdate><enddate>19960501</enddate><creator>KABASAKAL, L</creator><creator>ÖZKER, K</creator><creator>HAYWARD, M</creator><creator>AKANSEL, G</creator><creator>GRIFFITH, O</creator><creator>ISITMAN, A. T</creator><creator>HELLMAN, R</creator><creator>COLLIER, D</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960501</creationdate><title>Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance</title><author>KABASAKAL, L ; ÖZKER, K ; HAYWARD, M ; AKANSEL, G ; GRIFFITH, O ; ISITMAN, A. T ; HELLMAN, R ; COLLIER, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-18a46e74336312d218297967af4824cd0bcbf026b577fa052ff7e11ab2d1fa783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Glutathione - metabolism</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Radionuclide Imaging</topic><topic>Technetium Tc 99m Sestamibi - pharmacokinetics</topic><topic>Thallium Radioisotopes - pharmacokinetics</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KABASAKAL, L</creatorcontrib><creatorcontrib>ÖZKER, K</creatorcontrib><creatorcontrib>HAYWARD, M</creatorcontrib><creatorcontrib>AKANSEL, G</creatorcontrib><creatorcontrib>GRIFFITH, O</creatorcontrib><creatorcontrib>ISITMAN, A. T</creatorcontrib><creatorcontrib>HELLMAN, R</creatorcontrib><creatorcontrib>COLLIER, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KABASAKAL, L</au><au>ÖZKER, K</au><au>HAYWARD, M</au><au>AKANSEL, G</au><au>GRIFFITH, O</au><au>ISITMAN, A. T</au><au>HELLMAN, R</au><au>COLLIER, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance</atitle><jtitle>European Journal of Nuclear Medicine</jtitle><addtitle>Eur J Nucl Med</addtitle><date>1996-05-01</date><risdate>1996</risdate><volume>23</volume><issue>5</issue><spage>568</spage><epage>570</epage><pages>568-570</pages><issn>0340-6997</issn><eissn>1619-7089</eissn><coden>EJNMD9</coden><abstract>An in vitro study was designed to evaluate the uptake of sestamibi (MIBI) in P-glycoprotein (Pgp) and glutathione-associated (GSH) multidrug-resistant (MDR) cell lines. MIBI uptake was studied in various human breast carcinoma cell lines, i.e. in wild-type (MCF7/wt) cells, in adriamycin-resistant (MCF7/adr) cells which express Pgp and in melphalan-resistant (MCF7/mph) cells with increased levels of GSH. The effects of buthiomine sulphoximine (BSO) and verapamil on MIBI uptake were also studied in the MCF7/mph and MCF7/adr cells respectively. The cells were incubated for 1 h with a dose of 0.1 MBq thallium-201 and technetium-99m MIBI. Both MIBI and 201Tl uptakes were higher for MCF7/mph cells than for the other cells studied. The mean MIBI uptake in MCF7/adr cells was significantly lower than that in MCF7/wt cells (1.9%+/-0.5% vs 3. 1%.0.6%; P <0.01). Verapamil treatment increased the MIBI uptake in MCF7/adr cells (to 2.6%.0.3%; P <0.05). Treatment of MCF7/mph cells with BSO resulted in a significant reduction in GSH content (from 243.2+/-81.1 nmol/mg protein to 17.6+/-4.4 nmol/mg protein; P <0. 001). However, MIBI uptake in BSO-treated and untreated MCF7/mph cells was similar (4.43%+/-0.5% and 5.93%+/-1.7%, respectively; P >0. 1). This study suggests that the uptake of MIBI is not diminished by glutathione-associated drug resistance and that MIBI uptake in a tumour sample does not necessarily indicate that a cancer is sensitive to drugs.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>8698063</pmid><doi>10.1007/BF00833393</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6997 |
| ispartof | European Journal of Nuclear Medicine, 1996-05, Vol.23 (5), p.568-570 |
| issn | 0340-6997 1619-7089 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00833393 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Biological and medical sciences Breast Neoplasms - diagnostic imaging Breast Neoplasms - drug therapy Breast Neoplasms - pathology Drug Resistance, Neoplasm Female Glutathione - metabolism Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Radionuclide Imaging Technetium Tc 99m Sestamibi - pharmacokinetics Thallium Radioisotopes - pharmacokinetics Tumor Cells, Cultured Tumors |
| title | Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T22%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Technetium-99m%20sestamibi%20uptake%20in%20human%20breast%20carcinoma%20cell%20lines%20displaying%20glutathione-associated%20drug-resistance&rft.jtitle=European%20Journal%20of%20Nuclear%20Medicine&rft.au=KABASAKAL,%20L&rft.date=1996-05-01&rft.volume=23&rft.issue=5&rft.spage=568&rft.epage=570&rft.pages=568-570&rft.issn=0340-6997&rft.eissn=1619-7089&rft.coden=EJNMD9&rft_id=info:doi/10.1007/BF00833393&rft_dat=%3Cproquest_cross%3E78029933%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78029933&rft_id=info:pmid/8698063&rfr_iscdi=true |